As researchers estimate that nearly all Americans have been exposed to SARS-CoV-2, the virus that causes COVID-19, whether through infection or vaccination, we are no longer “immunologically naive”—in other words, our immune systems are familiar with certain variants of SARS-CoV-2. This familiarity can pose a problem for vaccine development.
Multipurpose vaccine shows new promise in the presence of pre-existing immunity
